Ocular Therapeutix stock tumbles as Q1 results miss estimates

Published 05/05/2025, 13:50
Ocular Therapeutix stock tumbles as Q1 results miss estimates

Investing.com -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) shares plunged 12.5% after the biopharmaceutical company reported first quarter results that fell short of analyst expectations.

The company, focused on developing therapies for retinal diseases, posted a loss of $0.38 per share for Q1 2025, wider than the $0.29 loss analysts had forecast. Revenue came in at $10.7 million, significantly below the consensus estimate of $17.07 million and down 27.6% YoY from $14.8 million.

Ocular attributed the revenue decline primarily to its pricing strategy impacting distributor stocking patterns and buying patterns by surgical centers and physicians’ offices. The company also cited the inclusion of its DEXTENZA product in Medicare’s Merit-based Incentive Payment System for 2025 as a factor.

Despite the earnings miss, Ocular highlighted progress in its clinical programs. The company’s SOL-1 Phase 3 trial for its AXPAXLI product in wet age-related macular degeneration remains on track for topline data in Q1 2026. Enrollment in the SOL-R Phase 3 trial continues to be strong following recent protocol changes.

"We continue to advance the SOL registrational program for our product candidate AXPAXLI in wet AMD (NASDAQ:AMD) with urgency and precision," said Pravin U. Dugel, Executive Chairman, President and CEO of Ocular Therapeutix.

The company ended the quarter with $349.7 million in cash and cash equivalents, which it believes will fund operations into 2028. Ocular expects net product revenue to increase in the remaining quarters of 2025 as clinicians adjust to recent changes and the company increases sales efforts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.